- Home
- GNTA vs KLRS Comparison
GNTA vs KLRS Comparison
Compare GNTA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | KLRS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 46.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | KLRS |
|---|---|---|
| Price | $1.93 | $5.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 136.9K | ★ 156.9K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $2.14 |
| 52 Week High | $10.00 | $12.90 |
Technical Indicators
Market Signals| Indicator | GNTA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 47.18 |
| Support Level | $1.35 | $6.04 |
| Resistance Level | $2.20 | $7.07 |
| Average True Range (ATR) | 0.23 | 0.69 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 58.76 | 30.29 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.